Table 3 Proportion of treated comorbid conditions
Share of diagnosed individuals with comorbidity-relevant prescription at baseline | |||
|---|---|---|---|
N diagnosed | N treated | % treated | |
Congestive heart failure (EI group 1) | 10,793 | 9514 | 88.1 |
Beta-blockers | 5093 | 53.5 | |
ACE inhibitors | 3995 | 42.0 | |
Angiotensin-I-antagonists | 1752 | 18.4 | |
Digitalis glycosides | 1038 | 10.9 | |
Diuretic drugs | 5114 | 53.8 | |
Cardiac arrhythmia (EI group 2) | 9694 | 5382 | 55.5 |
Beta-blockers | 4769 | 88.6 | |
Digitalis glycosides | 1256 | 23.3 | |
Anti-arrhythmic drugs | 512 | 9.5 | |
Valvular disease (EI group 3) | 5345 | 3957 | 74.0 |
Beta-blockers | 2536 | 64.1 | |
ACE inhibitors | 1806 | 45.6 | |
Diuretic drugs | 2691 | 68.0 | |
IHD | 11,632 | 9357 | 80.4 |
Statins | 3761 | 40.2 | |
Beta-blockers | 5730 | 61.2 | |
ACE inhibitors | 4292 | 45.9 | |
Angiotensin-I-antagonists | 1971 | 21.1 | |
Antiplatelet drugs | 2986 | 31.9 | |
Heparin (−derivates) | 1157 | 12.4 | |
Vitamin-K antagonists | 1187 | 12.7 | |
Hypertension without complications (EI group 6) | 19,059 | 17,594 | 92.3 |
Beta-blockers | 7255 | 41.2 | |
ACE inhibitors | 6433 | 36.6 | |
Angiotensin-I-antagonists | 3241 | 18.4 | |
Diuretic drugs | 4936 | 28.1 | |
Hypertension with complications (EI group 7) | 5866 | 5301 | 90.4 |
Beta-blockers | 2813 | 53.1 | |
ACE inhibitors | 2221 | 41.9 | |
Angiotensin-I-antagonists | 1222 | 23.1 | |
Diuretic drugs | 2427 | 45.8 | |
PH | 4537 | 1771 | 39.0 |
PAH drugs | 237 | 13.4 | |
Diuretic drugs | 1699 | 95.9 | |
COPD (EI group 10) | 20,595 | 9473 | 46.0 |
LABA | 2431 | 25.7 | |
LAMA | 4376 | 46.2 | |
ICS | 2138 | 22.6 | |
Peripheral vascular disorders (EI group 4) | 6692 | 3391 | 50.7 |
Antiplatelet drugs | 1566 | 46.2 | |
Heparin (−derivates) | 698 | 20.6 | |
Vitamin-K antagonists | 581 | 17.1 | |
Statins | 1928 | 56.9 | |
Diabetes without complications (EI group 11) | 6403 | 2505 | 39.1 |
Diabetes with complications (EI group 12) | 5025 | 3337 | 66.4 |
Depression (EI group 31) | 7410 | 2656 | 35.8 |
GERD | 5594 | 3629 | 64.9 |
PPI | 3545 | 97.7 | |
Histamin-H2 antagonists | 5594 | 99 | 2.7 |